Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Vibeke Strand

Rheumatology Portola Valley, CA Medical Doctor

NPI 1194882753 CMS profile 325924

306 Ramona Rd, Portola Valley, CA 94028

Open in the dashboard

General payments

$700,525

421 records reported · program years 2019–2025

Research payments

$70,437

Paid to them · 64 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$70,710 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Vibeke Strand of Portola Valley, CA is reported in the CMS Open Payments database as having received $700,525 across 421 general payments and $70,437 in research payments paid to them. Separately, studies naming them as principal investigator received $70,710 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $50,800 32
2025 Research $2,245 1
2024 General $74,898 43
2023 General $43,856 40
2023 Research $3,200 1
2022 General $114,428 65
2022 Research $12,740 13
2021 General $67,104 33
2021 Research $16,081 12
2020 General $143,266 69
2020 Research $24,822 20
2019 General $206,173 139
2019 Research $11,350 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vibeke Strand
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Vibeke Strand were reported at $50,800. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Vibeke Strand Rheumatology median Middle half National median
2019 $206,173 $744 $153–$2,687 $163
2020 $143,266 $462 $98–$2,027 $114
2021 $67,104 $531 $101–$2,153 $132
2022 $114,428 $627 $125–$2,303 $149
2023 $43,856 $741 $145–$2,524 $160
2024 $74,898 $830 $166–$2,660 $164
2025 $50,800 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $142,039 78 payments
  2. E.R. Squibb & Sons, L.L.C. $60,473 56 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $57,738 20 payments
  4. AstraZeneca UK Limited $47,563 19 payments
  5. Novartis Pharmaceuticals Corporation $45,503 30 payments
  6. Amgen Inc. $44,951 44 payments
  7. Pfizer Inc. $37,873 18 payments
  8. Horizon Therapeutics plc $35,144 14 payments
  9. AstraZeneca Pharmaceuticals LP $22,353 14 payments
  10. Whitehall International Inc $21,743 4 payments
  11. Other $185,144 124 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $545,270 212 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $56,997 26 payments
  3. Honoraria $50,238 11 payments
  4. Travel and Lodging $27,973 44 payments
  5. Grant $7,763 5 payments
  6. Food and Beverage $6,941 119 payments
  7. Compensation for serving as faculty or as a speaker for a medical education program $5,343 4 payments
Products named General payments · program years 2019–2025
  1. SAPHNELO $45,088 18 payments
  2. COSENTYX $43,713 20 payments
  3. XELJANZ $41,745 15 payments
  4. KRYSTEXXA $35,144 14 payments
  5. SKYRIZI $27,288 14 payments
  6. Tavneos $23,385 13 payments
  7. Zilretta $19,079 8 payments
  8. Sprifermin $17,409 4 payments
  9. INFLECTRA $12,513 1 payment
  10. Essure $11,950 12 payments
  11. Other $90,229 116 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. AbbVie, Inc. $18,843 7 payments
  2. Pfizer Inc. $12,880 12 payments
  3. Novartis Pharmaceuticals Corporation $8,801 11 payments
  4. Bioventus LLC $8,613 8 payments
  5. Endo Pharmaceuticals Inc. $8,050 5 payments
  6. Amgen Inc. $5,848 5 payments
  7. Novartis Pharma AG $3,655 5 payments
  8. Sanofi-Aventis U.S. LLC $2,104 8 payments
  9. Genzyme Corporation $1,643 3 payments

Records

485 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record